Ignite Creation Date:
2025-12-24 @ 8:02 PM
Ignite Modification Date:
2025-12-30 @ 9:21 AM
Study NCT ID:
NCT04006704
Status:
COMPLETED
Last Update Posted:
2021-07-06
First Post:
2019-07-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets
Sponsor:
Janssen Pharmaceutica N.V., Belgium
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-10-10
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-03-06
Completion Date Type:
ACTUAL
First Submit Date:
2019-07-02
First Submit QC Date:
None
Study First Post Date:
2019-07-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-01
Last Update Post Date:
2021-07-06
Last Update Post Date Type:
ACTUAL